Bio/Medical Technology Club of Houston Meeting

 
“Envisioning the Future of Platelet Therapy - ThromboVision”
 
Come hear Edward R. Teitel, President & CEO of ThromboVision, Inc., an HTC Client company, at the Bio/Medical Technology Club of Houston meeting.
 
ThromboVision, Inc.
 
For years, cardiovascular patients have been taking anti-platelet medications to prevent life-threatening adverse cardiovascular events such as heart attacks, strokes and stent occlusions—without knowing whether their therapies were effective. ThromboVision has developed a new medical device – the ThromboVision ThromboGuideTM (T-GuideTM) platelet therapy monitoring system.  This device provides a simple, inexpensive solution to help physicians and their patients monitor and assess anti-platelet therapies.  The T-Guide measures platelet aggregation using a patented light scattering technology which identifies and monitors the function of platelets and how they are affected by anti-platelet drugs such as aspirin (ASA) and clopidogrel (Plavix®). www.thrombovision.com

Pricing: Includes Breakfast Hospitality and Parking
$15 - Members with online reservations
$20 - Members with no reservations or non-members with online reservations
$25 - Non-members with no reservations
$5 – At the door with valid student ID
Speaker Edward R. Teitel, MD, JD, MBA
President & CEO ThromboVision, Inc. Dr. Teitel served as Senior Vice President and Chief Medical Officer at MicroMed Technology, Inc. (now MicroMed Cardiovascular, Inc., a public company) until leaving to help found and lead ThromboVision, Inc. As a part of senior management at MicroMed, Dr. Teitel participated in all aspects ...

President & CEO
ThromboVision, Inc.

Dr. Teitel served as Senior Vice President and Chief Medical Officer at MicroMed Technology, Inc. (now MicroMed Cardiovascular, Inc., a public company) until leaving to help found and lead ThromboVision, Inc. As a part of senior management at MicroMed, Dr. Teitel participated in all aspects of clinical trials and regulatory matters, business scope and fund raising activities, as well as legal matters. As chief medical officer for the DeBakey Left Ventricular Assist Device at MicroMed, Dr. Teitel acquired extensive experience in platelet function and anti-platelet therapy, especially relating to artificial surface devices. This background allowed Dr. Teitel to recognize the life saving and market potential of the T-Guide technology.


Before joining MicroMed Technology in 2002, Dr. Teitel practiced for many years as a board certified general and vascular surgeon. He founded, managed, and developed a multi-specialty group practice in Alabama until he closed his practice in 1997 to transition into corporate medicine and management. At that time he went on to earn his MBA at Auburn University and worked with a boutique investment banking firm, Colby Capital, in Atlanta where he worked to fund start-up companies in the life sciences. After completing law school in 2002, he joined the senior management team at MicroMed. 


Dr. Teitel earned his MD degree at the University of Texas Health Science Center at San Antonio, and completed his surgical residency at St. Mercy Medical Hospital in Pontiac, Michigan. He received his Juris Doctor degree from the University of Houston, with a focus in healthcare law, intellectual property and business law. Dr. Teitel holds a BS in chemistry from Sul Ross State University.

Full Description
Organizer BMTC

When

Tue, Nov. 7, 2006
7 a.m. - 8:30 a.m. US/Central

Where

Trevisio Restaurant (Water Wall Building in the Texas Medical Center), 6th Floor
6550 Bertner Ave (Off Holcombe Blvd, East of Fannin)
Houston, TX 77030